Opendata, web and dolomites

ProCanEx

Prostate cancer diagnostic assay based on protein kinase activity profiling in exosomes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ProCanEx project word cloud

Explore the words cloud of the ProCanEx project. It provides you a very rough idea of what is the project "ProCanEx" about.

plan    covered    markers    scientific    invasive    market    sources    profiling    altered    2017    diseases    platform    complementary    diagnosed    supports    composition    deadliest    men    kinases    newly    positive    levels    prostate    strategy    originating    painful    positives    diagnosis    business    exosomes    diagnostics    biopsies    probes    tissue    practicality    innovation    biomarker    antigen    circulating    17    45    assay    annually    measuring    worldwide    unnecessary    usd    tests    europeans    innovative    instrument    2012    cancer    technological    billion    mainly    financing    practical    detection    sustainability    diagnostic    patient    stratification    literature    sme    quantitative    specificity    licensee    70    care    combines    pca    performed    false    exosome    decisions    debated    screening    psa    disease    totalled    clinical    prognosis    discovered    treatment    protein    healthcare    sought    million    health    417    12    age   

Project "ProCanEx" data sheet

The following table provides information about the project.

Coordinator
KINASERA OU 

Organization address
address: UUS 63-55
city: TARTU
postcode: 50606
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Estonia [EE]
 Project website http://www.kinasera.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KINASERA OU EE (TARTU) coordinator 50˙000.00

Map

 Project objective

The objective of the innovation project is the development of novel biomarker-based non-invasive assay for prostate cancer (PCa) detection. 417 000 Europeans were diagnosed with PCa in 2012, about 12% of all new cancer cases of European men. The diagnosis and screening of PCa totalled 12 billion USD in 2012 and will reach 17.4 billion USD in 2017 since the PSA test is performed for men over 50 years of age annually. The PCa diagnostics market is mainly covered by the Prostate-Specific Antigen (PSA) test, the practicality of which is debated. The low specificity of the test means a high number of false positives, leading to unnecessary and painful procedures (biopsies, treatment, etc.). More than 45 million PSA tests are performed annually worldwide, while more than 9 million of those are positive, with around 70% false positives. Our assay is built on an innovative technological platform based on quantitative profiling of protein kinases in circulating exosomes. Recent scientific literature supports the potential of exosomes as diagnostic markers. Our assay combines two innovative approaches - newly discovered changes in exosome composition in cancer and probes for measuring altered levels of several protein kinases in exosomes originating from the cancer tissue. We will use the phase I of the SME instrument to make a detailed business plan, market research and evaluate technological, technical and practical issues. Collaboration with a potential licensee and complementary sources of financing for Phase II are sought. A detailed research plan will be conducted. Cancer diagnostics is among the main concerns for healthcare as cancer is among the deadliest diseases. Our proposal aims at development of innovative, non-invasive, highly reliable and cost-effective test for PCa, which would contribute to the sustainability of European health care system. Our strategy will enable patient stratification and/or prognosis of disease leading to the improved clinical decisions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROCANEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROCANEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More